DK1165115T3 - Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer - Google Patents

Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer

Info

Publication number
DK1165115T3
DK1165115T3 DK00916545T DK00916545T DK1165115T3 DK 1165115 T3 DK1165115 T3 DK 1165115T3 DK 00916545 T DK00916545 T DK 00916545T DK 00916545 T DK00916545 T DK 00916545T DK 1165115 T3 DK1165115 T3 DK 1165115T3
Authority
DK
Denmark
Prior art keywords
vascular permeability
modulation
tie2 receptor
receptor activators
mammal
Prior art date
Application number
DK00916545T
Other languages
Danish (da)
English (en)
Inventor
Chitra Suri
George D Yancopoulos
Donald Mcdonald
Gavin Thurston
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/286,033 external-priority patent/US6455035B1/en
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK1165115T3 publication Critical patent/DK1165115T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00916545T 1999-03-26 2000-03-20 Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer DK1165115T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12653999P 1999-03-26 1999-03-26
US09/286,033 US6455035B1 (en) 1999-03-26 1999-04-05 Angiopoietins and methods of use thereof
PCT/US2000/007336 WO2000057901A1 (en) 1999-03-26 2000-03-20 Modulation of vascular permeability by means of tie2 receptor activators

Publications (1)

Publication Number Publication Date
DK1165115T3 true DK1165115T3 (da) 2003-09-22

Family

ID=26824785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00916545T DK1165115T3 (da) 1999-03-26 2000-03-20 Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer

Country Status (14)

Country Link
EP (1) EP1165115B1 (de)
JP (1) JP2002540165A (de)
AT (1) ATE241380T1 (de)
AU (1) AU769198B2 (de)
CA (1) CA2368670C (de)
DE (1) DE60003011T2 (de)
DK (1) DK1165115T3 (de)
ES (1) ES2199804T3 (de)
HK (1) HK1043537A1 (de)
IL (2) IL145504A0 (de)
NO (1) NO329198B1 (de)
NZ (1) NZ514434A (de)
PT (1) PT1165115E (de)
WO (1) WO2000057901A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001291019A1 (en) 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1962903B1 (de) * 2005-12-15 2013-03-13 MedImmune Limited Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MX2010008099A (es) 2008-01-28 2010-08-04 Medimmune Ltd Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
DK2385763T3 (en) * 2009-01-12 2018-07-16 Aerpio Therapeutics Inc METHODS OF TREATING VASCULAR LEAK SYNDROME
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
ES2726946T3 (es) 2009-07-06 2019-10-10 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composiciones de los mismos y su uso en la prevención de la metástasis de las células cancerosas
BR112014008759A8 (pt) 2011-10-13 2017-09-12 Aerpio Therapeutics Inc Tratamento de doença ocular
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014233363B2 (en) 2013-03-15 2017-06-29 EyePoint, Inc. Compositions, formulations and methods for treating ocular diseases
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
EP3116503A4 (de) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta-hemmer
ES2894802T3 (es) 2015-09-23 2022-02-15 Aerpio Pharmaceuticals Inc Activadores de Tie-2 para su uso en el tratamiento de la presión intraocular
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
EP3962482A4 (de) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. Gegen den schlemm-kanal gerichtete tie-2-aktivatoren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
US5482930A (en) * 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
EP1283268A3 (de) * 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Rekombinantes Vasculäres Endothelzellen Wachstumsfaktor D (VEGF-D)
US6365154B1 (en) * 1998-09-28 2002-04-02 Smithkline Beecham Corporation Tie2 agonist antibodies

Also Published As

Publication number Publication date
HK1043537A1 (zh) 2002-09-20
EP1165115B1 (de) 2003-05-28
JP2002540165A (ja) 2002-11-26
IL145504A0 (en) 2002-06-30
PT1165115E (pt) 2003-10-31
AU3763400A (en) 2000-10-16
WO2000057901A1 (en) 2000-10-05
NO20014673L (no) 2001-11-22
CA2368670A1 (en) 2000-10-05
ATE241380T1 (de) 2003-06-15
NO20014673D0 (no) 2001-09-26
AU769198B2 (en) 2004-01-22
NO329198B1 (no) 2010-09-13
DE60003011D1 (de) 2003-07-03
IL145504A (en) 2008-08-07
EP1165115A1 (de) 2002-01-02
NZ514434A (en) 2003-11-28
ES2199804T3 (es) 2004-03-01
CA2368670C (en) 2012-06-05
DE60003011T2 (de) 2004-04-08

Similar Documents

Publication Publication Date Title
DK1165115T3 (da) Modulering af vaskulær permeabilitet ved hjælp af TIE2-receptor aktivatorer
DE59911670D1 (de) Glutamin-Thiazolidide und -Pyrrolidide sowie ihre Verwendung als Dipeptidylpeptidase IV Inhibitoren
TR200000782T2 (tr) Resorsinol türevleri.
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
TR200102773T2 (tr) Alkoksisilan yapısal birimleri olan poliüretan eriyikleri
DE60010098D1 (de) 28-epirapaloge
ID19242A (id) Pirometer untuk gas dapur api
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
ATE382060T1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
DE69632435D1 (de) Inhibitor des Hepatozytwachstumsfaktoraktivators
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
DE60116557D1 (de) Karl-Fischer-Reagenz
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
BR0114884A (pt) Compostos calcilìticos
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
PT1156999E (pt) Metodo para a preparacao de um beta-aminoester quiral
NZ331678A (en) Method of checking integrity of modified atmosphere package by placing gas indicator between package and liner
DE69631500D1 (de) Inhibitor des Hepatozytwachstumsfaktoraktivators
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
DE50010740D1 (de) Färbemittel und verwendung